|Articles|June 9, 2004
Santen Pharmaceuticals ends phaco device development
Phacor Inc., the California-based wholly owned subsidiary of Santen Pharmaceuticals Co. Ltd., ceased operations after 6 years of phacoemulsification system development.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Regeneron's EYLEA HD injection 8 mg approved by FDA for the treatment of macular edema following RVO
2
Precise Bio completes procedure using PB-001, a 3D-bioprinted corneal implant
3
EyePoint receives second consecutive positive recommendation from DSMC
4
Defining Retinal Vascular Diseases AMD, DME, RVO
5














































.png)


